Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients

Antinuclear Antibodies With a Nucleolar Pattern Are Associated With a Significant Reduction in the Overall Survival of Patients With Leukemia: A Retrospective Cohort Study

“…Most previous studies reported that the appearance of ANAs was associated with improved outcome in patients with cancer (3,4,23), possibly due to more vigorous activation of the immune system fighting against malignant cells (10,13,24). Despite contradictory reports, the presence of ANAs might result in a poor prognosis in patients treated with combinatorial immunotherapy and chemotherapy (25)(26)(27). Consistent with the aforementioned findings, the appearance of ANAs was associated with a poor prognosis in patients with leukemia in this study.…”

The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study

“…showed a tendency for increased frequency of total irAEs as well as severe irAEs, and the frequency of discontinuation of all treatment components due to severe AEs was significantly higher in the ANA-positive group than in the ANA-negative group. 17 These results were inconsistent with our data. Hayashi et al.…”

“…2 Also, Morimoto et al showed a tendency for increased frequency of total irAEs as well as severe irAEs, and the frequency of discontinuation of all treatment components due to severe AEs was significantly higher in the ANA-positive group than in the ANA-negative group. 17 The relationship between immune-related adverse events (A) or discontinuation (B) of immune checkpoint inhibitors and immune-related antibodies. AchR, acetylcholine esterase receptor; ANA, anti-nuclear antibody; GAD, glutamic acid decarboxylase; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; Neg, negative; PA, platelet-associated; Pos, positive; Tg, thyroglobulin; TPO, thyroid peroxidase.…”

“… 16 In our study, the ratio of females to males was higher than in previous studies. 2 , 17 Therefore, we guess that more patients with non-disease-specific ANA might be included in this present study.…”

Antiphospholipid Antibodies and Lipids in Hematological Malignancies

“…One of them is the anti-cytoplasmic neutrophil antibodies (ANCAs) [35]; associations of these antibodies' expression with cancer may coexist with a systemic and localized inflammatory response [36]. Additionally, the other antibodies' are the antinuclear antibodies (ANAs); they have been detected in multiple neoplasms [37][38][39], both hematological [40][41][42], in pulmonary [37,38], colorectal [37], or breast cancer, with high prevalence in these types of cancer [39].…”